Acute Coronary Syndrome (ACS) represents a spectrum of conditions associated with acute myocardial ischemia. As our understanding of the pathophysiology of ACS has evolved, so too have the strategies for its management. This article aims to provide an overview of the latest advancements and best practices in managing ACS.
Over the past decade, significant advancements have been made in the management of ACS. The introduction of high-sensitivity cardiac troponin assays has improved the early diagnosis of ACS. Furthermore, the advent of novel antiplatelet agents such as ticagrelor and prasugrel has enhanced the efficacy of dual antiplatelet therapy, reducing the risk of recurrent ischemic events.
Best practices in ACS management are guided by evidence-based clinical guidelines. Early risk stratification using tools such as the GRACE score is recommended to guide treatment decisions. For patients with ST-elevation myocardial infarction (STEMI), immediate reperfusion therapy is the standard of care. For non-STEMI patients, an early invasive strategy is preferred, particularly for those at high risk. Long-term management includes optimal medical therapy, secondary prevention measures, and cardiac rehabilitation.
Future research in ACS management is directed towards individualized patient care. This includes the development of precision medicine approaches, utilizing genomic and proteomic data to guide treatment decisions. Additionally, the role of novel imaging modalities in improving risk stratification and guiding revascularization strategies is being explored.
In conclusion, the management of ACS has substantially evolved over the past decade, with significant advancements in diagnostic and therapeutic strategies. Adherence to evidence-based best practices is crucial to improve patient outcomes. Future directions in ACS management include the development of precision medicine approaches and the use of novel imaging modalities.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation